117 related articles for article (PubMed ID: 31407032)
1. Prognostic and predictive value of Ki-67 in triple-negative breast cancer.
Wang W; Wu J; Zhang P; Fei X; Zong Y; Chen X; Huang O; He JR; Chen W; Li Y; Shen K; Zhu L
Oncotarget; 2016 May; 7(21):31079-87. PubMed ID: 27145269
[TBL] [Abstract][Full Text] [Related]
2. Calpain-1 Expression in Triple-Negative Breast Cancer: A Potential Prognostic Factor Independent of the Proliferative/Apoptotic Index.
Al-Bahlani SM; Al-Rashdi RM; Kumar S; Al-Sinawi SS; Al-Bahri MA; Shalaby AA
Biomed Res Int; 2017; 2017():9290425. PubMed ID: 28536704
[TBL] [Abstract][Full Text] [Related]
3. Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
Nagahashi M; Ling Y; Toshikawa C; Hayashida T; Kitagawa Y; Futamura M; Kuwayama T; Nakamura S; Yamauchi H; Yamauchi T; Kaneko K; Kanbayashi C; Sato N; Tsuchida J; Moro K; Nakajima M; Shimada Y; Ichikawa H; Lyle S; Miyoshi Y; Takabe K; Okuda S; Wakai T
Breast Cancer; 2023 Jul; 30(4):584-595. PubMed ID: 36930419
[TBL] [Abstract][Full Text] [Related]
4. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
[TBL] [Abstract][Full Text] [Related]
6. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Liu Y; Zugazagoitia J; Ahmed FS; Henick BS; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
Clin Cancer Res; 2020 Feb; 26(4):970-977. PubMed ID: 31615933
[TBL] [Abstract][Full Text] [Related]
7. KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance.
Arafah MA; Ouban A; Ameer OZ; Quek KJ
Breast Cancer (Auckl); 2021; 15():11782234211016977. PubMed ID: 34158798
[TBL] [Abstract][Full Text] [Related]
8. microRNA-181a promotes the oncogene S100A2 and enhances papillary thyroid carcinoma growth by mediating the expression of histone demethylase KDM5C.
Wang Y; Ye H; Yang Y; Li J; Cen A; Zhao L
J Endocrinol Invest; 2022 Jan; 45(1):17-28. PubMed ID: 34143366
[TBL] [Abstract][Full Text] [Related]
9. [Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques
in the Lung Cancer Immunotherapy].
Sun W; Zhou J; Zhou J
Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):36-42. PubMed ID: 33478189
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
Ng HHM; Lee RY; Goh S; Tay ISY; Lim X; Lee B; Chew V; Li H; Tan B; Lim S; Lim JCT; Au B; Loh JJH; Saraf S; Connolly JE; Loh T; Leow WQ; Lee JJX; Toh HC; Malavasi F; Lee SY; Chow P; Newell EW; Choo SP; Tai D; Yeong J; Lim TKH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847986
[TBL] [Abstract][Full Text] [Related]
11. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy.
Tan WCC; Nerurkar SN; Cai HY; Ng HHM; Wu D; Wee YTF; Lim JCT; Yeong J; Lim TKH
Cancer Commun (Lond); 2020 Apr; 40(4):135-153. PubMed ID: 32301585
[TBL] [Abstract][Full Text] [Related]
12. The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach.
Tan AS; Yeong JPS; Lai CPT; Ong CHC; Lee B; Lim JCT; Thike AA; Iqbal J; Dent RA; Lim EH; Tan PH
Virchows Arch; 2019 Dec; 475(6):709-725. PubMed ID: 31407032
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence.
Lai CPT; Yeong JPS; Tan AS; Ong CHC; Lee B; Lim JCT; Thike AA; Iqbal J; Dent RA; Lim EH; Tan PH
Breast Cancer Res Treat; 2019 Nov; 178(2):295-305. PubMed ID: 31410680
[TBL] [Abstract][Full Text] [Related]
15. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.
Pan Y; Yuan Y; Liu G; Wei Y
PLoS One; 2017; 12(2):e0172324. PubMed ID: 28235003
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
Ozretic P; Alvir I; Sarcevic B; Vujaskovic Z; Rendic-Miocevic Z; Roguljic A; Beketic-Oreskovic L
Int J Biol Markers; 2018 Jan; 33(1):109-115. PubMed ID: 28777433
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
